Are Wall Street Analysts Bullish on DexCom’s Stock?

California-based DexCom, Inc. (DXCM) is a leading medical technology company specializing in continuous glucose monitoring (CGM) systems for people with diabetes. With a market cap of $22.3 billion, the company develops wearable sensors and software platforms that allow users to track glucose levels in real time without the need for frequent fingerstick testing.

Shares of the medical device company have underperformed the broader market over the past 52 weeks. DXCM stock has declined 33.7% over this time frame, while the broader S&P 500 Index ($SPX) has gained 27.3%. Moreover, the stock has decreased 12.9% on a YTD basis, slightly outpacing SPX's 9.6% gain.